Plasma DNA can be analyzed by approaches targeting specific tumor-associated genes (e.g., mutations in the EGFR gene in non-small cell lung carcinoma (NSCLC)) or non-targeted screening approaches such as array CGH, whole-genome sequencing, or exome sequencing) [25,26]. The gene discussed is EGFR; the disease is neoplasm.